File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s13148-019-0669-2
- Scopus: eid_2-s2.0-85065503631
- PMID: 31064412
- WOS: WOS:000467444000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
Title | Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact |
---|---|
Authors | |
Keywords | DNA methylation miR-340-5p Multiple myeloma Overall survival XIAP |
Issue Date | 2019 |
Publisher | BioMed Central Ltd. The Journal's web site is located at http://www.clinicalepigeneticsjournal.com |
Citation | Clinical Epigenetics, 2019, v. 11, article no. 71 How to Cite? |
Abstract | Background:
miR-340-5p, localized to 5q35, is a tumor suppressor miRNA implicated in multiple cancers. As a CpG island is present at the putative promoter region of its host gene, RNF130, we hypothesized that the intronic miR-340-5p is a tumor suppressor miRNA epigenetically silenced by promoter DNA methylation of its host gene in multiple myeloma.
Results:
By pyrosequencing-confirmed methylation-specific PCR, RNF130/miR-340 was methylated in 8/15 (53.3%) myeloma cell lines but not normal plasma cells. Methylation correlated inversely with the expression of both miR-340-5p and RNF130. In completely methylated WL-2 and RPMI-8226R cells, 5-AzadC treatment led to demethylation and re-expression of miR-340-5p. In primary samples, RNF130/miR-340 methylation was detected in 4 (22.2%) monoclonal gammopathy of undetermined significance, 15 (23.8%) diagnostic myeloma, and 7 (23.3%) relapsed myeloma. RNF130/miR-340 methylation at diagnosis was associated with inferior overall survival (median 27 vs. 68 months; P = 3.944E−5). In WL-2 cells, overexpression of miR-340-5p resulted in reduced cellular proliferation [MTS, P = 0.002; verified in KMS-12-PE (P = 0.002) and RPMI-8226R (P = 2.623E−05) cells], increased cell death (trypan blue, P = 0.005), and enhanced apoptosis by annexin V-PI staining. Moreover, by qRT-PCR, overexpression of miR-340-5p led to repression of both known targets (CCND1 and NRAS) and bioinformatically predicted targets in MAPK signaling (MEKK1, MEKK2, and MEKKK3) and apoptosis (MDM4 and XIAP), hence downregulation of phospho-ERK1/2 and XIAP by Western blot. Furthermore, by qRT-PCR, in CD138-sorted primary samples (n = 37), miR-340-5p and XIAP were inversely correlated (P = 0.002). By luciferase assay, XIAP was confirmed as a direct target of miR-340-5p via targeting of the distal but not proximal seed region binding site.
Conclusions:
Collectively, tumor-specific methylation-mediated silencing of miR-340-5p is likely an early event in myelomagenesis with adverse survival impact, via targeting multiple oncogenes in MAPK signaling and apoptosis, thereby a tumor suppressive miRNA in myeloma. |
Persistent Identifier | http://hdl.handle.net/10722/272288 |
ISSN | 2023 Impact Factor: 4.8 2023 SCImago Journal Rankings: 1.727 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Z | - |
dc.contributor.author | Wong, KY | - |
dc.contributor.author | Calin, GA | - |
dc.contributor.author | Chng, WJ | - |
dc.contributor.author | Chan, GCF | - |
dc.contributor.author | Chim, CS | - |
dc.date.accessioned | 2019-07-20T10:39:20Z | - |
dc.date.available | 2019-07-20T10:39:20Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Clinical Epigenetics, 2019, v. 11, article no. 71 | - |
dc.identifier.issn | 1868-7075 | - |
dc.identifier.uri | http://hdl.handle.net/10722/272288 | - |
dc.description.abstract | Background: miR-340-5p, localized to 5q35, is a tumor suppressor miRNA implicated in multiple cancers. As a CpG island is present at the putative promoter region of its host gene, RNF130, we hypothesized that the intronic miR-340-5p is a tumor suppressor miRNA epigenetically silenced by promoter DNA methylation of its host gene in multiple myeloma. Results: By pyrosequencing-confirmed methylation-specific PCR, RNF130/miR-340 was methylated in 8/15 (53.3%) myeloma cell lines but not normal plasma cells. Methylation correlated inversely with the expression of both miR-340-5p and RNF130. In completely methylated WL-2 and RPMI-8226R cells, 5-AzadC treatment led to demethylation and re-expression of miR-340-5p. In primary samples, RNF130/miR-340 methylation was detected in 4 (22.2%) monoclonal gammopathy of undetermined significance, 15 (23.8%) diagnostic myeloma, and 7 (23.3%) relapsed myeloma. RNF130/miR-340 methylation at diagnosis was associated with inferior overall survival (median 27 vs. 68 months; P = 3.944E−5). In WL-2 cells, overexpression of miR-340-5p resulted in reduced cellular proliferation [MTS, P = 0.002; verified in KMS-12-PE (P = 0.002) and RPMI-8226R (P = 2.623E−05) cells], increased cell death (trypan blue, P = 0.005), and enhanced apoptosis by annexin V-PI staining. Moreover, by qRT-PCR, overexpression of miR-340-5p led to repression of both known targets (CCND1 and NRAS) and bioinformatically predicted targets in MAPK signaling (MEKK1, MEKK2, and MEKKK3) and apoptosis (MDM4 and XIAP), hence downregulation of phospho-ERK1/2 and XIAP by Western blot. Furthermore, by qRT-PCR, in CD138-sorted primary samples (n = 37), miR-340-5p and XIAP were inversely correlated (P = 0.002). By luciferase assay, XIAP was confirmed as a direct target of miR-340-5p via targeting of the distal but not proximal seed region binding site. Conclusions: Collectively, tumor-specific methylation-mediated silencing of miR-340-5p is likely an early event in myelomagenesis with adverse survival impact, via targeting multiple oncogenes in MAPK signaling and apoptosis, thereby a tumor suppressive miRNA in myeloma. | - |
dc.language | eng | - |
dc.publisher | BioMed Central Ltd. The Journal's web site is located at http://www.clinicalepigeneticsjournal.com | - |
dc.relation.ispartof | Clinical Epigenetics | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | DNA methylation | - |
dc.subject | miR-340-5p | - |
dc.subject | Multiple myeloma | - |
dc.subject | Overall survival | - |
dc.subject | XIAP | - |
dc.title | Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact | - |
dc.type | Article | - |
dc.identifier.email | Wong, KY: kwanumu@hku.hk | - |
dc.identifier.email | Chan, GCF: gcfchan@hku.hk | - |
dc.identifier.email | Chim, CS: jcschim@hku.hk | - |
dc.identifier.authority | Chan, GCF=rp00431 | - |
dc.identifier.authority | Chim, CS=rp00408 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s13148-019-0669-2 | - |
dc.identifier.pmid | 31064412 | - |
dc.identifier.pmcid | PMC6505104 | - |
dc.identifier.scopus | eid_2-s2.0-85065503631 | - |
dc.identifier.hkuros | 299540 | - |
dc.identifier.volume | 11 | - |
dc.identifier.spage | article no. 71 | - |
dc.identifier.epage | article no. 71 | - |
dc.identifier.isi | WOS:000467444000001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1868-7075 | - |